Evidence map›Paper›PMID 32860544›Full record

Observational studyJournal of neurology2021

One-year survival of patients with high-grade glioma discharged alive from the intensive care unit.

Maxens Decavèle, Nicolas Gatulle, Nicolas Weiss, Isabelle Rivals, Ahmed Idbaih, Sophie Demeret, Julien Mayaux, Martin Dres, Elise Morawiec, Khe Hoang-Xuan and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Impact of intensive care unit admission on the resumption of treatment in patients with cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Financial toxicity in patients with glioblastoma.Journal of neuro-oncology · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maxens DecavèleMédecine Intensive Et Réanimation (Département R3S), Service de Pneumologie, AP-HP, Site Pitié-Salpêtrière, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Service de Neurologie 2-Mazarin, 75013, Paris, France. maxens.decavele@aphp.fr.ORCID http://orcid.org/0000-0003-3552-5053
Nicolas GatulleMédecine Intensive Et Réanimation (Département R3S), Service de Pneumologie, AP-HP, Site Pitié-Salpêtrière, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Service de Neurologie 2-Mazarin, 75013, Paris, France.
Nicolas WeissUnité de Médecine Intensive Réanimation Neurologique, Département de Neurologie, DMU Neurosciences Et Institut de Neurosciences Translationnelles, AP-HP.Sorbonne IHU-A-ICM, Hôpital de La Pitié-Salpêtrière, Université Paris, Paris, France.
Isabelle RivalsUMRS1158 Neurophysiologie Respiratoire Expérimentale Et Clinique, INSERM, Sorbonne Université, 75005, Paris, France.
Ahmed IdbaihInserm, CNRS, UMR S 1127, Institut du Cerveau Et de La Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Sorbonne Université, 75013, Paris, France.
Sophie DemeretUnité de Médecine Intensive Réanimation Neurologique, Département de Neurologie, DMU Neurosciences Et Institut de Neurosciences Translationnelles, AP-HP.Sorbonne IHU-A-ICM, Hôpital de La Pitié-Salpêtrière, Université Paris, Paris, France.
Julien MayauxUMRS1158 Neurophysiologie Respiratoire Expérimentale Et Clinique, INSERM, Sorbonne Université, 75005, Paris, France.
Martin DresMédecine Intensive Et Réanimation (Département R3S), Service de Pneumologie, AP-HP, Site Pitié-Salpêtrière, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Service de Neurologie 2-Mazarin, 75013, Paris, France.
Elise MorawiecUMRS1158 Neurophysiologie Respiratoire Expérimentale Et Clinique, INSERM, Sorbonne Université, 75005, Paris, France.
Khe Hoang-XuanInserm, CNRS, UMR S 1127, Institut du Cerveau Et de La Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Sorbonne Université, 75013, Paris, France.
Thomas SimilowskiMédecine Intensive Et Réanimation (Département R3S), Service de Pneumologie, AP-HP, Site Pitié-Salpêtrière, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Service de Neurologie 2-Mazarin, 75013, Paris, France.
Alexandre DemouleMédecine Intensive Et Réanimation (Département R3S), Service de Pneumologie, AP-HP, Site Pitié-Salpêtrière, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Service de Neurologie 2-Mazarin, 75013, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOnly limited data are available regarding the long-term prognosis of patients with high-grade glioma discharged alive from the intensive care unit. We sought to quantify 1-year mortality and evaluate the association between mortality and (1) functional status, and (2) management of anticancer therapy in patients with high-grade glioma discharged alive from the intensive care unit. PATIENTS AND

methodsRetrospective observational cohort study of patients with high-grade glioma admitted to two intensive care units between January 2009 and June 2018. Functional status was assessed by the Karnofsky Performance Status. Anticancer therapy after discharge was classified as (1) continued (unchanged), (2) modified (changed or stopped), or (3) initiated (for newly diagnosed disease).

resultsNinety-one high-grade glioma patients (73% of whom had glioblastoma) were included and 78 (86%) of these patients were discharged alive from the intensive care unit. Anticancer therapy was continued, modified, and initiated in 41%, 42%, and 17% of patients, respectively. Corticosteroid therapy at the time of ICU admission [odds ratio (OR) 0.07] and cancer progression (OR 0.09) was independently associated with continuation of anticancer therapy. The mortality rate 1 year after ICU admission was 73%. On multivariate analysis, continuation of anticancer therapy (OR 0.18) and Karnofsky performance status on admission (OR 0.90) were independently associated with lower 1-year mortality.

conclusionThe presence of high-grade glioma is not sufficient to justify refusal of intensive care unit admission. Performance status and continuation of anticancer therapy are associated with higher survival after intensive care unit discharge. PREVIOUS PRESENTATION: Preliminary results were presented at the most recent congress of the French Intensive Care Society, Paris, 2019.

Indexed as

GliomaPatient DischargeCritical CareHospital MortalityHumansIntensive Care UnitsRetrospective StudiesAnticancer therapyGliomaIntensive care unitMalignant brain tumorsOne-year survivalPerformance status

Identifiers

PMID32860544
PMCPMC7456207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.